BERLIN—Ejaculatory dysfunction affects almost half of men undergoing screening for prostate cancer, a study found.
Jochen Walz, MD, of the University of Montreal, Canada, and his colleagues studied 1,273 men (mean age 57.6 years) without clinical evidence of prostate cancer who completed the self-administered Danish Prostate Symptom Score for sexual dysfunction.
The questionnaire quantifies the rate of reduced ejaculatory volume, ejaculatory pain, and the rate of coexistent erectile dysfunction (ED). Ejaculatory dysfunction was defined as reduced ejaculatory volume.
A total of 563 men (46%) had ejaculatory dysfunction; of these, 356 (66%) were bothered by the condition, the investigators reported here at the 22nd European Association of Urology Congress. Ejaculatory pain was reported by 134 (11%). Among these men, 118 (89%) reported associated bother. In addition, 554 men (44%) reported ED and 403 of them (73%) reported associated bother.
Since virtually all men will be affected by ejaculatory dysfunction after definitive treatment for localized prostate cancer, the researchers concluded that it is important to observe that half of these men already have underlying ejaculatory dysfunction before treatment. Baseline ejaculatory dysfunction is a source of bother in two thirds of men, and should be considered when treatment-related quality of life is assessed, the team stated. “When treating patients for prostate cancer, we must evaluate ejaculatory volume.”